News

The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.

A pooled analysis of 2 phase 3 trials of fenfluramine demonstrate the clinical potential of the drug for patients with Dravet syndrome.

SynapCell and Motac Neuroscience recently announced a novel biomarker, BetaPark [evo], for Parkinson disease progression. The chief innovation officer at SynapCell provided insight into the clinical implications of this discovery.

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton and principal investigator of the PROSPECT study, offered insight into the clinical impact and advantages of the Cala Trio neuromodulation device.

The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation shared his unique perspective on spinal cord injury as someone who experienced it.

Ganaxolone proves effective in phase 2 trial in patients with status epilepticus, with a median time to status cessation of 5 minutes.

The section chief of pediatric neurology at Nationwide Children’s Hospital discusses the realities parents face when exploring CBD to treat epilepsy.

After pulling the plug on trials in March 2019, Biogen has announced that an expanded analysis revealed significant positive results for aducanumab in patients with early Alzheimer disease.

Mia Minen, MD, MPH, sat down for an interview to discuss why behavioral therapies could be an effective and easily accessible treatment for posttraumatic headaches following events like concussions.

The wrist-worn wearable neuromodulation device for essential tremor was shown to be safe and efficacious in the PROSPECT trial, with more than 50% of patients experiencing a ≥50% improvement in tremor "power" or severity.

Partnership between NIH and NINDS hopes to identify disease biomarkers and spur new clinical trials for frontotemporal lobar degeneration.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered her perspective on the adherence challenges in treating obstructive sleep apnea with continuous positive airway pressure.

The VMAT2 inhibitor marketed as Austedo by Teva Pharmaceuticals was associated with clinically meaningful long-term treatment benefit in patients with tardive dyskinesia, showing higher response rates than those observed in short-term trials.

At the 2019 American Academy of Neurology Conference, Mia Minen, MD, MPH took the time to sit down and discuss the behavioral therapies associated with treating migraine.

New study results suggest that a wearable ECG device can predict nonconvulsive seizures with a sensitivity of 93.1% and all seizures with a sensitivity of 90.5%.

Neurology News Network for the week ending October 19, 2019.

At the 2019 American Academy of Neurology Annual Meeting, Mia Minen, MD, MPH, discussed the opportunities that the increasing number of mobile health users presents for migraine treatment.

The director of pediatric epilepsy at Northeast Regional Epilepsy Group and co-director of epileptology at Hackensack University Medical Center provided context to these findings to explain how soticlestat can address challenges in developmental epileptic encephalopathies, as well as what may be next in its advancement.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine provided her perspective on the differences in OSA prevalence for men and women.

New trials and research partnerships have launched with hopes to find answers for the terminal disease.

The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation shared insight into the work the center is doing to address the secondary complications and challenges faced by individuals with spinal cord injury.

The director of pediatric epilepsy at Northeast Regional Epilepsy Group and co-director of epileptology at Hackensack University Medical Center spoke about soticlestat and what can be gleaned from data thus far.

Sperling sat down with NeurologyLive at AAIC 2019 to discuss her thoughts on efforts to detect and treat Alzheimer early on in the disease.

Recent study results suggest that relative seizure reduction is an equivalent predictor of post-surgery quality of life in epilepsy to seizure freedom. Study author Lara Jehi, MD, offered insight into the value of these data.

A first-of-its-kind study has explored the social and professional impacts that tardive dyskinesia-related movements can have on individuals with the condition, as well outward perceptions.

Results of a phase 2 trial in patients with Friedreich’s ataxia leaves hope for the future, with regulatory submission on the agenda.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered perspective on the currently available interventions for OSA, including the use of upper airway neurostimulation.

Relative seizure reduction was as equally strong a predictor of patient quality of life after epilepsy surgery as seizure freedom in a recent study, with absolute reduction proving to be the worst model surveyed.

The oral selective adenosine A 2A receptor antagonist was approved in August as adjunctive treatment to levodopa/carbidopa for patients with Parkinson disease who experience off episodes.

New study results suggest that thrombectomy may have similar rates of favorable neurologic outcomes and a comparable safety profile in both pediatric and adult patients with stroke.